Can Spravato (esketamine nasal spray) be used concurrently with Sudafed (pseudoephedrine)?

Spravato and Sudafed: Concurrent Use

Spravato (esketamine) and Sudafed (pseudoephedrine) should NOT be used together due to the significant risk of dangerous blood pressure elevation and cardiovascular complications. 1

Critical Safety Concern: Blood Pressure Elevation

The FDA label for Spravato explicitly warns about blood pressure increases and recommends close monitoring when esketamine is used with psychostimulants or sympathomimetics like pseudoephedrine. 1

• Esketamine causes systolic and diastolic blood pressure increases that peak approximately 40 minutes after administration and last approximately 4 hours 1
• Approximately 3% to 19% of Spravato-treated patients experience increases ≥40 mmHg systolic and/or ≥25 mmHg diastolic BP in the first 1.5 hours after administration 1
• Pseudoephedrine independently raises systolic blood pressure by approximately 1 mmHg and heart rate by 2.83 beats/min through α-adrenergic agonist activity 2, 3
• When combined, these vasoconstrictive effects are additive and can precipitate hypertensive crisis 3

Spravato Contraindications Relevant to This Combination

Spravato is contraindicated in patients with aneurysmal vascular disease, arteriovenous malformation, or history of intracerebral hemorrhage because blood pressure increases pose serious risk 1

• Before prescribing Spravato, patients with cardiovascular and cerebrovascular conditions must be carefully assessed 1
• The combination with pseudoephedrine amplifies cardiovascular risk beyond acceptable limits 1

Monitoring Requirements for Spravato Alone

• Blood pressure must be assessed prior to each Spravato administration 1
• If BP is elevated (generally >140/90 mmHg) before dosing, therapy should be delayed 1
• BP monitoring is mandatory for at least 2 hours post-administration, with measurements around 40 minutes post-dose and subsequently as clinically warranted 1
• Patients experiencing hypertensive crisis symptoms (chest pain, shortness of breath) or hypertensive encephalopathy (sudden severe headache, visual disturbances, seizures, diminished consciousness, focal neurological deficits) require immediate emergency care 1

Additional Risks of Concurrent Use

Beyond blood pressure concerns, the combination poses multiple overlapping adverse effects:

• Both agents can cause CNS effects: Spravato causes sedation (48-61% of patients), dissociation (61-84%), and cognitive impairment 1
• Pseudoephedrine causes insomnia, irritability, palpitations, tremor, and loss of appetite 2
• These effects may be additive and compromise patient safety during the mandatory 2-hour post-Spravato observation period 1

Safe Alternatives for Nasal Congestion in Spravato Patients

If nasal congestion treatment is needed during Spravato therapy, use these cardiovascular-neutral alternatives:

• Intranasal corticosteroids (fluticasone, mometasone) are the preferred first-line option with no blood pressure effects 2, 3
• Nasal saline irrigation provides symptomatic relief without systemic absorption or cardiovascular impact 2, 3
• Second-generation antihistamines without decongestant (loratadine, cetirizine, fexofenadine) are safe alternatives that do not affect blood pressure 3
• Topical oxymetazoline may be used for ≤3 days maximum with minimal systemic effects, but must be strictly time-limited to prevent rhinitis medicamentosa 2

Clinical Algorithm for Managing This Scenario

If a patient on Spravato requires decongestant therapy:

1. Immediately discontinue or avoid pseudoephedrine 1
2. Substitute with intranasal corticosteroid as first-line alternative 2, 3
3. If rapid relief needed, use topical oxymetazoline for ≤3 days only 2
4. After 3 days, transition to intranasal corticosteroid for sustained management 2
5. Never combine multiple sympathomimetic agents with Spravato 3, 1

Common Pitfalls to Avoid

• Never assume the "average" 1 mmHg pseudoephedrine effect is clinically insignificant in Spravato patients—individual responses are highly variable and the combination creates unpredictable risk 3, 1
• Do not use phenylephrine oral tablets as a "safer" alternative—while less systemically absorbed, oral phenylephrine is also ineffective due to extensive first-pass metabolism 2
• Avoid extending topical decongestant use beyond 3 days, as rebound congestion will worsen symptoms and potentially lead to inappropriate pseudoephedrine use 2
• Remember that over-the-counter cold preparations often contain multiple sympathomimetics—carefully review all ingredients before recommending any OTC product 3